MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
P/S ratio for MaxCyte, Inc. (MXCT)
P/S ratio as of 2023: 11.76
According to MaxCyte, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 11.76. At the end of 2022 the company had a P/S ratio of 12.55.
P/S ratio history for MaxCyte, Inc. from 2012 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 11.76 |
| 2022 | 12.55 |
| 2021 | 27.24 |
| 2020 | 45.13 |
| 2019 | 44.34 |
| 2018 | 52.21 |
| 2017 | 59.13 |
| 2016 | 46.44 |
| 2015 | 79.55 |
| 2014 | 103.15 |
| 2013 | 108.60 |
| 2012 | 146.06 |